Dr. Margaret Liu

PAX Therapeutics

Developing vaccines for pandemics: Why equity and education are key

In this video, Dr. Margaret Liu, a leader in the science of vaccines and a global health expert, explains how her early research on vaccine development became critical to the COVID-19 pandemic, and how she is currently working with the World Health Organization to establish guidance on vaccines to enable their global usage. Liu also reveals the advantages of T cell vaccines, explores some of the key learnings from the on-going pandemic, and highlights the critical role of education in overcoming future health crises. Dr. Liu was a keynote speaker at this year's AACC Annual Meeting with a talk titled: COVID-19: Vaccines and the tango of viral evolution and host immune responses.



LIKE 2


Dr. Margaret Liu
Health Sciences

Dr. Margaret Liu

Biography

Margaret Liu, MD, DSchc, MDhc, FISV Principal, CEO, PAX Therapeutics, Chairman of the Board, International Society for Vaccines More
Follow Margaret

Dr. Margaret Liu

PAX Therapeutics

Dr. Margaret A. Liu is known internationally as an expert in the fields of gene delivery, vaccines, immunotherapy, and global health. Dr. Liu obtained an M.D. from Harvard Medical School and completed her clinical and research training at Massachusetts General Hospital/Harvard Medical School and MIT, in addition to passing the Epreuve pour le Diplôme d’Enseignement à l’Unanimité du Jury in piano at L’Ecole Normale de Musique de Paris. She has pioneered two important new technologies for vaccines and for treating cancer (DNA vaccines and bifunctional antibodies) for which she has received numerous awards internationally and two honorary doctorates including an MD honoris causa, given by the Karolinska Institutet in Stockholm, where she had been previously invited to lecture by the Nobel committee and has an appointment in the Department of Medicine. She also is an Adjunct Full Professor, Department of Microbiology & Immunology, School of Medicine, at UCSF. She is known as “The Mother of DNA Vaccines” and is the scientific lead for the WHO drafting group writing guidelines for mRNA vaccines. Dr. Liu is CEO of PAX Therapeutics, which is developing gene-based therapy of tendon and ligament repair. As Principal of ProTherImmune, she consults for companies, investment firms, universities, and scientific non-governmental and governmental organizations. She is also the Chairman of the Board and President Emeritus of the International Society for Vaccines.